[1]
|
J. E. Lavine, J. B. Schwimmer, M. L. Van Natta, J. P. Molleston, K. F. Murray and P. Rosenthal, “Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial,” JAMA, Vol. 305, No. 16, 2011, pp. 1659-1668. http://dx.doi.org/10.1001/jama.2011.520
|
[2]
|
C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, Y. C. Liu and A. J. McCullough, “Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological severity,” Gastroenterology, Vol. 116, No. 6, 1999, pp. 1413-1419. http://dx.doi.org/10.1016/S0016-5085(99)70506-8
|
[3]
|
T. Pacana and A. J. Sanyal, “Vitamin E and Nonalcoholic fatty Liver Disease,” Current Opinion in Clinical Nutrition & Metabolic Care, Vol. 15, No. 6, 2012, pp. 641-648. http://dx.doi.org/10.1097/MCO.0b013e328357f747
|
[4]
|
C. P. Day, “Pathogenesis of Steatohepatitis,” Best Practice & Research Clinical Gastroenterology, Vol. 16, No. 5, 2002, pp. 663-678. http://dx.doi.org/10.1053/bega.2002.0333
|
[5]
|
M. G. Traber and J. F. Stevens, “Vitamins C and E: Beneficial Effects from a Mechanistic Perspective,” Free Radical Biology & Medicine, Vol. 51, No. 5, 2011, pp. 1000-1013. http://dx.doi.org/10.1016/j.freeradbiomed.2011.05.017
|
[6]
|
C. Y. Chang, C. K. Argo, A. M. Al-Osaimi and S. H. Caldwell, “Therapy of NAFLD: Antioxidants and Cytoprotective Agents,” Journal of Clinical Gastroenterology, Vol. 40, Suppl. 1, 2006, pp. S51-S60.
|
[7]
|
G. Nowak, D. Bakajsova, C. Hayes, M. Hauer-Jensen and C. M. Compadre, “Gamma-Tocotrienol Protects against Mitochondrial Dysfunction and Renal Cell Death,” Journal of Pharmacology and Experimental Therapeutics, Vol. 340, No. 2, 2012, pp. 330-338. http://dx.doi.org/10.1124/jpet.111.186882
|
[8]
|
G. R. Buettner, “The Pecking Order of Free Radicals and Antioxidants: Lipid Peroxidation, Alpha-Tocopherol, and Ascorbate,” Archives of Biochemistry and Biophysics, Vol. 300, No. 2, 1993, pp. 535-543. http://dx.doi.org/10.1006/abbi.1993.1074
|
[9]
|
M. Kawanaka, S. Mahmood, G. Niiyama, A. Izumi, A. Kamei and H. Ikeda, “Control of Oxidative Stress and Reduction in Biochemical Markers by Vitamin E Treatment in Patients with Nonalcoholic Steatohepatitis: A Pilot Study,” Hepatology Research, Vol. 29, No. 1, 2004, pp. 39-41. http://dx.doi.org/10.1016/j.hepres.2004.02.002
|
[10]
|
A. Kuhad and K. Chopra, “Attenuation of Diabetic Nephropathy by Tocotrienol: Involvement of NFkB Signaling Pathway,” Life Sciences, Vol. 84, No. 9-10, 2009, pp. 296-301. http://dx.doi.org/10.1016/j.lfs.2008.12.014
|
[11]
|
J. E. Lavine, “Vitamin E Treatment of Nonalcoholic Steatohepatitis in Children: A Pilot Study,” The Journal of Pediatrics, Vol. 136, No. 6, 2000, pp. 734-738.
|
[12]
|
E. Bugianesi, E. Gentilcore, R. Manini, S. Natale, E. Vanni and N. Villanova, “A Randomized Controlled Trial of Metformin Versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease,” The American Journal of Gastroenterology, Vol. 100, No. 5, 2005, pp. 1082-1090. http://dx.doi.org/10.1111/j.1572-0241.2005.41583.x
|
[13]
|
T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino and A. Terano, “Plasma Transforming Growth Factor-Beta1 Level and Efficacy of Alpha-Tocopherol in Patients with Non-Alcoholic Steatohepatitis: A Pilot Study,” Alimentary Pharmacology & Therapeutics, Vol. 15, No. 10, 2001, pp. 1667-1672. http://dx.doi.org/10.1046/j.1365-2036.2001.01083.x
|
[14]
|
F. Yakaryilmaz, S. Guliter, B. Savas, O. Erdem, R. Ersoy and E. Erden, “Effects of Vitamin E Treatment on Peroxisome Proliferator-Activated Receptor-Alpha Expression and Insulin Resistance in Patients with Non-Alcoholic Steatohepatitis: Results of a Pilot Study,” Internal Medicine Journal, Vol. 37, No. 4, 2007, pp. 229-235. http://dx.doi.org/10.1111/j.1445-5994.2006.01295.x
|
[15]
|
A. J. Sanyal, N. Chalasani, K. V. Kowdley, A. McCullough, A. M. Diehl and N. M. Bass, “Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis,” The New England Journal of Medicine, Vol. 362, No. 18, 2010, pp. 1675-1685. http://dx.doi.org/10.1056/NEJMoa0907929
|
[16]
|
G. Paolisso, G. Di Maro, D. Galzerano, F. Cacciapuoti, G. Varricchio and M. Varricchio, “Pharmacological Doses of Vitamin E and Insulin Action in Elderly Subjects,” The American Journal of Clinical Nutrition, Vol. 59, No. 6, 1994, pp. 1291-1296.
|
[17]
|
T. Costacou, B. Ma, I. B. King and E. J. Mayer-Davis, “Plasma and Dietary Vitamin E in Relation to Insulin Secretion and Sensitivity,” Diabetes, Obesity and Metabolism, Vol. 10, No. 3, 2008, pp. 223-228. http://dx.doi.org/10.1111/j.1463-1326.2006.00683.x
|
[18]
|
X. H. Shen, Q. Y. Tang, J. Huang and W. Cai, “Vitamin E Regulates Adipocytokine Expression in a Rat Model of Dietary-Induced Obesity,” Experimental Biology and Medicine (Maywood), Vol. 235, No. 1, 2010, pp. 47-51. http://dx.doi.org/10.1258/ebm.2009.009122
|
[19]
|
I. P. Tzanetakou, I. P. Doulamis, L. M. Korou, G. Agrogiannis, I. S. Vlachos and A. Pantopoulou, “Water Soluble Vitamin E Administration in Wistar Rats with Nonalcoholic Fatty Liver Disease,” The Open Cardiovascular Medicine Journal, Vol. 6, 2012, pp. 88-97. http://dx.doi.org/10.2174/1874192401206010088
|
[20]
|
A. J. Sanyal, P. S. Mofrad, M. J. Contos, C. Sargeant, V. A. Luketic and R. K. Sterling, “A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis,” Clinical Gastroenterology and Hepatology, Vol. 2, No. 12, 2004, pp. 1107-1115. http://dx.doi.org/10.1016/S1542-3565(04)00457-4
|
[21]
|
K. J. Stewart, A. C. Bacher, K. Turner, J. G. Lim, P. S. Hees andE. P. Shapiro, “Exercise and Risk Factors Associated with Metabolic Syndrome in Older Adults,” American Journal of Preventive Medicine, Vol. 28, No. 1, 2005, pp. 9-18. http://dx.doi.org/10.1016/j.amepre.2004.09.006
|
[22]
|
L. E. McCurdy, K. E. Winterbottom, S. S. Mehta and J. R. Roberts, “Using Nature and Outdoor Activity to Improve Children’s Health,” Current Problems in Pediatric and Adolescent Health Care, Vol. 40, No. 5, 2010, pp. 102-117. http://dx.doi.org/10.1016/j.cppeds.2010.02.003
|
[23]
|
M. Kugelmas, D. B. Hill, B. Vivian, L. Marsano and C. J. McClain, “Cytokines and NASH: A Pilot Study of the Effects of Lifestyle Modification and Vitamin E,” Hepatology, Vol. 38, No. 2, 2003, pp. 413-419. http://dx.doi.org/10.1053/jhep.2003.50316
|
[24]
|
P. Vajro, C. Mandato, A. Franzese, E. Ciccimarra and S. Lucariello, “Vitamin E Treatment in Pediatric obesity-Related Liver Disease: A Randomized Study,” Journal of Pediatric Gastroenterology and Nutrition, Vol. 38, No. 1, 2004, pp. 48-55. http://dx.doi.org/10.1097/00005176-200401000-00012
|
[25]
|
J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner, J. M. Clark and K. V. Kowdley, “Vitamin E and changes in Serum alanine Aminotransferase Levels in Patients with Non-Alcoholic Steatohepatitis,” Alimentary Pharmacology & Therapeutics, Vol. 38, No. 2, 2013, pp. 134-143. http://dx.doi.org/10.1111/apt.12352
|
[26]
|
E. D’Adamo, M. L. Marcovecchio, C. Giannini, T. de Giorgis and V. Chiavaroli, “Improved Oxidative Stress and Cardio-Metabolic Status in Obese Prepubertal Children with Liver Steatosis Treated with Lifestyle Combined with Vitamin E,” Free Radical Research, Vol. 47, No. 3, 2013, pp. 146-153. http://dx.doi.org/10.3109/10715762.2012.755262
|
[27]
|
S. A. Harrison, S. Torgerson, P. Hayashi, J. Ward and S. Schenker, “Vitamin E and Vitamin C Treatment Improves Fibrosis in Patients with Nonalcoholic Steatohepatitis,” The American Journal of Gastroenterology, Vol. 98, No. 11, 2003, pp. 2485-2490. http://dx.doi.org/10.1111/j.1572-0241.2003.08699.x
|
[28]
|
V. Nobili, M. Manco, R. Devito, P. Ciampalini and F. Piemonte, “Effect of Vitamin E on Aminotransferase Levels and Insulin Resistance in Children with Non-Alcoholic fatty Liver Disease,” Alimentary Pharmacology & Therapeutics, Vol. 24, No. 11-12, 2006, pp. 1553-1561. http://dx.doi.org/10.1111/j.1365-2036.2006.03161.x
|
[29]
|
G. Ersoz, F. Gunsar, Z. Karasu, S. Akay, Y. Batur and U. S. Akarca, “Management of Fatty Liver Disease with Vitamin E and C Compared to Ursodeoxycholic Acid Treatment,” The Turkish Journal of Gastroenterology, Vol. 16, No. 3, 2005, pp. 124-128.
|
[30]
|
T. Foster, M. J. Budoff, S. Saab, N. Ahmadi and C. Gordon, “Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial,” The American Journal of Gastroenterology, Vol. 106, No. 1, 2011, pp. 71-77. http://dx.doi.org/10.1038/ajg.2010.299
|
[31]
|
M. Trauner, T. Claudel, P. Fickert, T. Moustafa and M. Wagner, “Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism,” Digestive Diseases, Vol. 28, No. 1, 2010, pp. 220-224. http://dx.doi.org/10.1159/000282091
|
[32]
|
M. Kiyici, M. Gulten, S. Gurel, S. G. Nak, E. Dolar, G. Savci, S. B. Adim, O. Yerci and F. Memik, “Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis,” Canadian Journal of Gastroenterology, Vol. 17, No. 12, 2003, pp. 713-718.
|
[33]
|
K. Madan, Y. Batra, D. S. Gupta, B. Chander and K. D. Anand Rajan, “Vitamin E-Based Therapy Is Effective in Ameliorating Transaminasemia in Nonalcoholic Fatty Liver Disease,” Indian Journal of Gastroenterology, Vol. 24, No. 6, 2005, pp. 251-255.
|
[34]
|
J. F. Dufour, C. M. Oneta, J. J. Gonvers, F. Bihl, A. Cerny, J. M. Cereda, J. F. Zala, B. Helbling, M. Steuerwald and A. Zimmermann, “Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid with Vitamin E in Nonalcoholic Steatohepatitis,” Clinical Gastroenterology and Hepatology, Vol. 4, No. 12, 2006, pp. 1537-1543. http://dx.doi.org/10.1016/j.cgh.2006.09.025
|
[35]
|
T. Cho, Y. J. Kim and S. S. Paik, “The Efficacy of Pharmacological Treatment in Pediatric Nonalcoholic Fatty Liver Disease,” Pediatric Gastroenterology, Hepatology and Nutrition, Vol. 15, No. 4, 2012, pp. 256-265. http://dx.doi.org/10.5223/pghn.2012.15.4.256
|
[36]
|
M. L. Balmer, K. Siegrist, A. Zimmermann and J. F. Dufour, “Effects of Ursodeoxycholic Acid in Combination with Vitamin E on Adipokines and Apoptosis in Patients with Nonalcoholic Steatohepatitis,” Liver International, Vol. 29, No. 8, 2009, pp. 1184-1188. http://dx.doi.org/10.1111/j.1478-3231.2009.02037.x
|
[37]
|
F. Pietu, O. Guillaud, T. Walter, M. Vallin, V. Hervieu, J. Y. Scoazec and J. Dumortier, “Ursodeoxycholic Acid with vitamin E in Patients with Nonalcoholic Steatohepatitis: Long-Term Results,” Clinics and Research in Hepatology and Gastroenterology, Vol. 36, No. 2, 2012, pp. 146-155. http://dx.doi.org/10.1016/j.clinre.2011.10.011
|
[38]
|
N. Chalasani, Z. Younossi, J. E. Lavine, A. M. Diehl, E. M. Brunt, K. Cusi, M. Charlton and A. J. Sanyal, “The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology,” Gastroenterology, Vol. 142, No. 7, 2012, pp. 1592-1609. http://dx.doi.org/10.1053/j.gastro.2012.04.001
|
[39]
|
D. Berry, J. K. Wathen and M. Newell, “Bayesian Model Averaging in Meta-Analysis: Vitamin E Supplementation and Mortality,” Clinical Trials, Vol. 6, No. 1, 2009, pp. 28-41. http://dx.doi.org/10.1177/1740774508101279
|
[40]
|
D. P. Vivekananthan, M. S. Penn, S. K. Sapp, A. Hsu and E. J. Topol, “Use of Antioxidant Vitamins for the Prevention of Cardiovascular Disease: Meta-Analysis of Randomised Trials,” Lancet, Vol. 361, No. 9374, 2003, pp. 2017-2023. http://dx.doi.org/10.1016/S0140-6736(03)13637-9
|
[41]
|
J. Gerss and W. Kopcke, “The Questionable Association of Vitamin E Supplementation and Mortality—Inconsistent Results of Different Meta-Analytic Approaches,” Cellular and Molecular Biology (Noisy-le-Grand), Vol. 55(Suppl), 2009, pp. OL1111-OL1120.
|
[42]
|
G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-Analysis,” JAMA, Vol. 297, No. 8, 2007, pp. 842-857. http://dx.doi.org/10.1001/jama.297.8.842
|
[43]
|
E. R. Miller III, R. Pastor-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel and E. Guallar, “Meta-Analysis: HighDosage Vitamin E Supplementation May Increase All-Cause Mortality,” Annals of Internal Medicine, Vol. 142, No. 1, 2005, pp. 37-46. http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00110
|
[44]
|
H. D. Sesso, J. E. Buring, W. G. Christen, T. Kurth, C. Belanger, J. MacFadyen, V. Bubes, J. E. Manson, R. J. Glynn and J. M. Gaziano, “Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II Randomized Controlled Trial,” JAMA, Vol. 300, No. 18, 2008, pp. 2123-2133. http://dx.doi.org/10.1001/jama.2008.600
|
[45]
|
E. A. Klein, I. M. Thompson Jr., C. M. Tangen, J. J. Crowley, M. S. Lucia, P. J. Goodman, et al., “Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT),” JAMA, Vol. 306, No. 14, 2011, pp. 1549-1556. http://dx.doi.org/10.1001/jama.2011.1437
|